Navigation Links
Orexigen® Therapeutics Presents Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
Date:10/3/2011

ound at www.orexigen.com.

Forward-Looking Statements

Orexigen cautions you that statements included in this press release and the conference call that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements.  These statements are based on the Company's current beliefs and expectations.  These forward-looking statements include statements regarding: the use of validated models to predict the long-term risk of CV disease, CV mortality, myocardial infarction and stroke with Contrave and the potential impact of long-term treatment with Contrave; the ability of such models to predict the successful outcome of a cardiovascular outcomes trial; the ability for Contrave to enhance the activation of brain regions following exposure to food cues to help patients control food cravings; the study design for, and the timing and feasibility of, the CVOT; the potential for resubmission and approval of an NDA based on interim results of the CVOT; the potential for Contrave to effectively treat obesity; and the prospects for ultimate approval of an NDA for Contrave.The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved.  Actual results may differ from those set forth in this release and the conference call due to the risk and uncertainties inherent in Orexigen's business, including, without limitation: Orexigen's ability to maintain and raise sufficient capital to fund the CVOT and maintain its other operations; the uncertainty of the FDA approval process, including requirements for additional clinical and non-clinical studies or other commitments prior to the resubmission and approval of an NDA f
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
2. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
3. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
4. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
5. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
6. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
7. Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
8. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
9. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
10. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
11. Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... April 16, 2015  Amgen (NASDAQ: AMGN ) ... financial results on Tuesday, April 21, 2015, after the ... be followed by a conference call with the investment ... from Amgen will be Robert A. Bradway , ... Amgen,s senior management team. Live audio of ...
(Date:4/16/2015)... , April 16, 2015 Today, Kenneth C. ... & Co., Inc., was elected chairman of the Board of ... Board meeting, PhRMA,s president and CEO John J. Castellani ... 2016.  New Officers Elected to PhRMA Board ... succeeds Ian C. Read , chairman and CEO of ...
(Date:4/16/2015)...  Rosewind Corporation (OTCMKTS: RSWN) announced today that ... newly formed specialty healthcare company focused on redox-modulated ... disorders. The merged company, which is expected to ... and incorporates the pipeline assets of both Vyrix ... to build a late-stage and commercial pipeline of ...
Breaking Medicine Technology:Amgen Announces Webcast Of 2015 First Quarter Financial Results 2Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 2Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 3Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 4Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 5Rosewind Corporation Shifts Focus to Develop Late-Stage Therapeutics for Urological and Related Conditions 2Rosewind Corporation Shifts Focus to Develop Late-Stage Therapeutics for Urological and Related Conditions 3
... TAINAN, Taiwan, Aug. 31 /PRNewswire-Asia/ -- ... ... var shortURL = ""; ... we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; ...
... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ... for (var r in data.results) { first_result = data.results[r]; break; } for (var key in first_result) { ...
Cached Medicine Technology:ScinoPharm to Invest in Tanvex Biologics 2ScinoPharm to Invest in Tanvex Biologics 3ScinoPharm to Invest in Tanvex Biologics 4ScinoPharm to Invest in Tanvex Biologics 5ScinoPharm to Invest in Tanvex Biologics 6PharmaVentures Appoints Paul Phull as Senior Director 2PharmaVentures Appoints Paul Phull as Senior Director 3PharmaVentures Appoints Paul Phull as Senior Director 4PharmaVentures Appoints Paul Phull as Senior Director 5PharmaVentures Appoints Paul Phull as Senior Director 6
(Date:4/18/2015)... 2015 On April 14th, 2015, Symantec released ... which they say, “exposes a tactical shift by cyberattackers.” With ... were introduced in 2014 - almost a million a day ... to be identified and patched by prominent manufacturers – as ... doing business in a digital world can be fraught with ...
(Date:4/17/2015)... 2015 Heritage Woods of McLeansboro, a ... Living Week Celebration on April 20 with a day ... mind, body and soul. , The community, which is ... older adults of all incomes, including those on Medicaid, ... Supportive Living Week is observed every April and highlights ...
(Date:4/17/2015)... Alcohol and Violence , The National Council on ... driving has been the focus of much public and ... between alcohol and crime received less public attention. , ... assault, and their relationship to alcohol have been clearly ... in America were drinking alcohol at the time of ...
(Date:4/17/2015)... 17, 2015 Consumers who prefer to ... modifications can now use the Insurance Pros USA website ... policy rates that are featured by leading companies quoting ... that are offered are mixed between three of the ... 79. There are now term, universal and whole policies ...
(Date:4/17/2015)... Most dental patients are not aware that ... overseas by foreign dental laboratories, according to the U.S. ... more than 40 states by their respective state boards ... Laboratories has created the “What’s In Your ... the consequences that could be associated with using poorly-made ...
Breaking Medicine News(10 mins):Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 3Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 4Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 5Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 3Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 2Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 3Health News:General Life Insurance Policy Rates Added to Quotation System at Insurance Website Online 2Health News:National Association Urges Transparency in Dental Industry 2
... WAKEFIELD, Massachusetts, Feb. 14 /PRNewswire-FirstCall/ - NUCRYST,Pharmaceuticals Corp. (NASDAQ: ... year ended December 31, 2007. Net loss narrowed to ... $30.1 million. This compares to a net loss,of $10.5 ... $24.4 million in,the previous year. The lower net loss ...
... TSTF ), a national provider of healthcare and administrative,staffing ... ended December 31, 2007., Income from operations for ... as compared to a loss of $0.8 million in ... $0.04 million or,$0.00 per share compared to a loss ...
... Consumer Protection ... Against Aetna,s Propofol Decision, NEW YORK, ... use of Propofol, the "gold standard" anesthesia agent available,to ... outcry amongst physicians, their associations and consumers.,Today, the Gastroenterologists ...
... screening mammograms with computer-aided detection (CAD) is more efficient ... the first reader in a double reading program, according ... in Charlotte, NC. In addition, the readings with CAD ... , The double reading method consisted of the mammogram ...
... Has Assisted Over 6 Million Americans Since Its,Inception ... Denials, NEWPORT NEWS, Va., Feb. 14 ... organization providing,information and services to millions of patients ... are unable to obtain access,to healthcare because of ...
... More than 40 percent of the worlds oceans are ... according to a new study that will appear in ... NOAAs National Oceanographic Data Center in Silver Spring, Md., ... Human Impact on Marine Ecosystems, joined a team of ...
Cached Medicine News:Health News:NUCRYST Pharmaceuticals announces year-end results 2Health News:NUCRYST Pharmaceuticals announces year-end results 3Health News:NUCRYST Pharmaceuticals announces year-end results 4Health News:NUCRYST Pharmaceuticals announces year-end results 5Health News:NUCRYST Pharmaceuticals announces year-end results 6Health News:NUCRYST Pharmaceuticals announces year-end results 7Health News:NUCRYST Pharmaceuticals announces year-end results 8Health News:NUCRYST Pharmaceuticals announces year-end results 9Health News:NUCRYST Pharmaceuticals announces year-end results 10Health News:NUCRYST Pharmaceuticals announces year-end results 11Health News:NUCRYST Pharmaceuticals announces year-end results 12Health News:TeamStaff Reports First Quarter Net Income and $0.7 Million Income Improvement From Continuing Operations Over Prior Year 2Health News:TeamStaff Reports First Quarter Net Income and $0.7 Million Income Improvement From Continuing Operations Over Prior Year 3Health News:TeamStaff Reports First Quarter Net Income and $0.7 Million Income Improvement From Continuing Operations Over Prior Year 4Health News:TeamStaff Reports First Quarter Net Income and $0.7 Million Income Improvement From Continuing Operations Over Prior Year 5Health News:TeamStaff Reports First Quarter Net Income and $0.7 Million Income Improvement From Continuing Operations Over Prior Year 6Health News:TeamStaff Reports First Quarter Net Income and $0.7 Million Income Improvement From Continuing Operations Over Prior Year 7Health News:TeamStaff Reports First Quarter Net Income and $0.7 Million Income Improvement From Continuing Operations Over Prior Year 8Health News:TeamStaff Reports First Quarter Net Income and $0.7 Million Income Improvement From Continuing Operations Over Prior Year 9Health News:National Health Care Alliance Welcomes New Members 2Health News:National Health Care Alliance Welcomes New Members 3Health News:National Health Care Alliance Welcomes New Members 4Health News:Single reader with CAD more efficient, yields fewer false positives, and possibly more sensitive 2Health News:Leading National Patient Advocacy Group Delivers Warning to U.S. Patients: Having Health Insurance Does NOT Mean Your Medical Needs Will Be Covered 2Health News:Leading National Patient Advocacy Group Delivers Warning to U.S. Patients: Having Health Insurance Does NOT Mean Your Medical Needs Will Be Covered 3Health News:New study shows extent of harmful human influences on global ecosystems 2
Stratasis Urethral Sling is intended for implantation to reinforce soft tissues where weakness exists. Supplied sterile in peel-open packages. Intended for one-time use....
Used for retrograde pyelogram. The tip configuration occludes the ureteral orifice and stabilizes the catheter by temporarily wedging in the orifice. Supplied sterile in peel-open packages. Intended ...
Used for drainage and retrograde pyelogram. Supplied sterile in peel-open packages. Intended for one-time use....
Used for directing a flexible tipped wire guide in the ureter. The angled tip allows passage of the catheter past a ureteral stone in preparation for E.S.W.L. Supplied sterile in peel-open packages. ...
Medicine Products: